Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
06:46pm, Friday, 18'th Jul 2025
In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
02:46pm, Friday, 18'th Jul 2025
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on high
Discover comprehensive insights with the Livestock Identification Market Companies Quadrant. This analysis evaluates over 100 firms, spotlighting the Top 25 EVA Films leaders, focusing on key players,
Merck & Co., Inc. (MRK) Presents at HIV Investor Event Transcript
06:24pm, Thursday, 17'th Jul 2025
Merck & Co., Inc. (NYSE:MRK ) HIV Investor Event July 17, 2025 9:00 AM ET Company Participants Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Eliav Barr - Chief Medical Officer &
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
10:46am, Thursday, 17'th Jul 2025
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
08:15am, Thursday, 17'th Jul 2025
One of the biggest concerns with healthcare giant Merck (MRK 1.12%) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating billion
Why Merck Is A Better Dividend Stock Than Gilead Sciences
03:08pm, Wednesday, 16'th Jul 2025
I reiterate my Hold rating on Merck & Co., Inc. and downgrade Gilead Sciences, Inc. to Sell, as MRK outperforms on dividend growth and valuation metrics. Compared to GILD, MRK features a longer divide
Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet
10:31am, Wednesday, 16'th Jul 2025
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
07:00am, Wednesday, 16'th Jul 2025
Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces
Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know
06:51pm, Tuesday, 15'th Jul 2025
In the closing of the recent trading day, Merck (MRK) stood at $81.52, denoting a -2.57% move from the preceding trading day.
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
01:55pm, Tuesday, 15'th Jul 2025
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
MRK's Buyout Spree to Broaden Product Portfolio: Can it Aid Growth?
11:25am, Monday, 14'th Jul 2025
Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill
09:31am, Monday, 14'th Jul 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluati
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of V
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill
01:15pm, Friday, 11'th Jul 2025
MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.
